Victoria Alvarez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victoria Alvarez has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Eliecer Coto
Genética Molecular-Laboratorio de Medicina-Fundación Renal (IRSIN-FRIAT), Hospital Universitario Central Asturias, Oviedo, Spain
10 shared publications Eliecer Coto
Hospital Universitario Central de Asturias
9 shared publications- Germán Morís
Servcio de Neurología, HUCA, Oviedo, Asturias, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Departmento de Medicina, Universidad de Oviedo, Spain
9 shared publications - Lorena de Mena
Genética Molecular-Laboratorio de Medicina, Hospital Universitario Central de Asturias, Oviedo, Spain
7 shared publications Lucía F. Cardo
Genética Molecular-Laboratorio de Medicina, Hospital Universitario Central de Asturias, 33006, Oviedo, Spain
7 shared publications- Manuel Menéndez-González
Facultad de Medicina y Ciencias de la Salud, Universidad de Oviedo, Calle Julián Clavería s/n, 33006 Oviedo, Spain
7 shared publications
Latest Publications
- 5 October 2014
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 54 (4) , 830-836
MiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects
The deregulation of several microRNAs (miRNAs) has been associated with neurodegenerative processes, including Parkinson’s disease (PD). Our aim was to characterize the level of miRNAs in the substantia nigra (SN) of PD patients and healthy donors. This is an important issue to characterize new putative markers and therapeutic targets for PD. RNA was extracted from the SN of postmortem PD (n = 8) and healthy (n = 4) subjects, and the level of 733 human miRNAs was assayed with TaqMan low-density arrays (TLDAs). Overall, there was a miRNA downregulation in the SN of patients. The mean level of 11 miRNAs was significantly different (p < 0.05) between patients and controls, with 10 downregulated among the patients. MiR-198, -135b, -485-5p, and -548d were the best candidates and were quantified with individual TaqMan assays in the 12 samples. MiR-135b showed the most significant difference between patients and healthy donors. The bioinformatic analysis suggested that this miRNA could bind to genes implicated in several neurodegenerative pathways.
- 5 October 2014
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 54 (4) , 830-836
MiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects
The deregulation of several microRNAs (miRNAs) has been associated with neurodegenerative processes, including Parkinson’s disease (PD). Our aim was to characterize the level of miRNAs in the substantia nigra (SN) of PD patients and healthy donors. This is an important issue to characterize new putative markers and therapeutic targets for PD. RNA was extracted from the SN of postmortem PD (n = 8) and healthy (n = 4) subjects, and the level of 733 human miRNAs was assayed with TaqMan low-density arrays (TLDAs). Overall, there was a miRNA downregulation in the SN of patients. The mean level of 11 miRNAs was significantly different (p < 0.05) between patients and controls, with 10 downregulated among the patients. MiR-198, -135b, -485-5p, and -548d were the best candidates and were quantified with individual TaqMan assays in the 12 samples. MiR-135b showed the most significant difference between patients and healthy donors. The bioinformatic analysis suggested that this miRNA could bind to genes implicated in several neurodegenerative pathways.
- 10 September 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (6) , 3075-3076
Profile of microRNAs in the plasma of hypertrophic cardiomyopathy patients compared to healthy controls
- 10 September 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (6) , 3075-3076
Profile of microRNAs in the plasma of hypertrophic cardiomyopathy patients compared to healthy controls
- 1 August 2013
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 23 (8) , 445-448
A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients
The CYP3A5*3 and CYP3A4*1B alleles have been related with tacrolimus (Tac) dose requirements. The rare CYP3A4*22 variant has also been associated with a significantly lower Tac dose. We genotyped the three single-nucleotide polymorphisms in 206 kidney-transplanted patients who received Tac as the primary immunosuppressor. CYP3A5*1 and CYP3A4*1B allele carriers received a significantly higher Tac dose (PT) in one patient. We concluded that CYP3A5*3 and CYP3A4*1B were the main determinants of the Tac dose-adjusted blood concentration in our cohort of renal-transplanted patients.
- 1 August 2013
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 23 (8) , 445-448
A search for new CYP3A4 variants as determinants of tacrolimus dose requirements in renal-transplanted patients
The CYP3A5*3 and CYP3A4*1B alleles have been related with tacrolimus (Tac) dose requirements. The rare CYP3A4*22 variant has also been associated with a significantly lower Tac dose. We genotyped the three single-nucleotide polymorphisms in 206 kidney-transplanted patients who received Tac as the primary immunosuppressor. CYP3A5*1 and CYP3A4*1B allele carriers received a significantly higher Tac dose (PT) in one patient. We concluded that CYP3A5*3 and CYP3A4*1B were the main determinants of the Tac dose-adjusted blood concentration in our cohort of renal-transplanted patients.
- 18 July 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (14) , 2032-2033
No differential DNA methylation of PARK2 in brain of Parkinson's disease patients and healthy controls
- 18 July 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (14) , 2032-2033
No differential DNA methylation of PARK2 in brain of Parkinson's disease patients and healthy controls
- Open Access
- 30 March 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 260 (5) , 1420-1422
Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls
- 30 March 2013
- Published by Springer Nature in Journal of Neurology
- Vol. 260 (5) , 1420-1422
Open AccessProfile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls
- 1 March 2013
- Published by Wiley in Clinical Genetics
- Vol. 83 (3) , 257-262
SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V
Sánchez‐Ferrero E, Coto E, Beetz C, Gámez J, Corao A, Díaz M, Esteban J, del Castillo E, Moris G, Infante J, Menéndez M, Pascual‐Pascual SI, López de Munaín A, Garcia‐Barcina MJ, Alvarez V on behalf of the Genetics of Spastic Paraplegia study group. SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V.Mutations in the SPG7 gene were initially reported in patients with autosomal recessive hereditary spastic paraplegia (HSP). Recent works suggested a dominant effect for some SPG7 mutations. To characterize the SPG7 mutational spectrum in a large cohort of Spanish HSP patients, we sequenced the whole SPG7 gene in a total of 285 Spastic Paraplegia patients. Large gene rearrangements were also ascertained in some patients. We found a total of 14 SPG7 mutations (12 new) in 14 patients; 2 were large deletions. All the mutation carriers had an adult onset age but only five (35%) had a complicated phenotype. We identified a single mutation in 13 patients. Familial analysis suggested a dominant inheritance for one (p.Leu78*) of these mutations. Carriers of the rare p.A510V variant were significantly more frequent in patients vs healthy controls (3% vs 1%), suggesting a pathogenic role for this SPG7 variant. We reported a high frequency of patients with only one SPG7 mutation, and a putative pathogenic role for the p.A510V variant.
- 1 March 2013
- Published by Wiley in Clinical Genetics
- Vol. 83 (3) , 257-262
SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V
Sánchez‐Ferrero E, Coto E, Beetz C, Gámez J, Corao A, Díaz M, Esteban J, del Castillo E, Moris G, Infante J, Menéndez M, Pascual‐Pascual SI, López de Munaín A, Garcia‐Barcina MJ, Alvarez V on behalf of the Genetics of Spastic Paraplegia study group. SPG7 mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V.Mutations in the SPG7 gene were initially reported in patients with autosomal recessive hereditary spastic paraplegia (HSP). Recent works suggested a dominant effect for some SPG7 mutations. To characterize the SPG7 mutational spectrum in a large cohort of Spanish HSP patients, we sequenced the whole SPG7 gene in a total of 285 Spastic Paraplegia patients. Large gene rearrangements were also ascertained in some patients. We found a total of 14 SPG7 mutations (12 new) in 14 patients; 2 were large deletions. All the mutation carriers had an adult onset age but only five (35%) had a complicated phenotype. We identified a single mutation in 13 patients. Familial analysis suggested a dominant inheritance for one (p.Leu78*) of these mutations. Carriers of the rare p.A510V variant were significantly more frequent in patients vs healthy controls (3% vs 1%), suggesting a pathogenic role for this SPG7 variant. We reported a high frequency of patients with only one SPG7 mutation, and a putative pathogenic role for the p.A510V variant.
- Open Access
- 30 December 2012
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 50 (2) , 264-269
Mutational Screening of PARKIN Identified a 3′ UTR Variant (rs62637702) Associated with Parkinson’s Disease
PRKN mutations have been linked to Parkinson’s disease (PD). Most of the mutational screenings have focused on the coding exons. The 3′ untranslated region (UTR) could also harbor functionally relevant nucleotide changes. We performed a mutational screening of PRKN in a cohort of early-onset PD patients (n = 235) from Spain. We found 16 mutations (five new): 16 patients (7 %) carried two mutations and only one mutation was found in 28 (12 %). Patients with two mutations had significantly lower mean age (30 ± 9 years) compared to patients with one (40 ± 7) or no mutation (42 ± 7). We found a total of 15 nucleotide variants (three new) in the 3′ UTR region. The frequency of carriers of the rare rs62637702 G allele (*94A/G) was significantly lower among the patients compared to healthy controls (n = 418) (0.03 vs. 0.004; p < 0.001), suggesting a protective role for this allele. In order to investigate the basal effect of this variant, we performed luciferase assays. No different basal activity was observed between the two alleles. In conclusion, the rs62637702 polymorphism was associated with PD. This could be a surrogate marker for disease risk, in linkage disequilibrium with other non-identified functional variant.
- 30 December 2012
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 50 (2) , 264-269
Open AccessMutational Screening of PARKIN Identified a 3′ UTR Variant (rs62637702) Associated with Parkinson’s Disease
PRKN mutations have been linked to Parkinson’s disease (PD). Most of the mutational screenings have focused on the coding exons. The 3′ untranslated region (UTR) could also harbor functionally relevant nucleotide changes. We performed a mutational screening of PRKN in a cohort of early-onset PD patients (n = 235) from Spain. We found 16 mutations (five new): 16 patients (7 %) carried two mutations and only one mutation was found in 28 (12 %). Patients with two mutations had significantly lower mean age (30 ± 9 years) compared to patients with one (40 ± 7) or no mutation (42 ± 7). We found a total of 15 nucleotide variants (three new) in the 3′ UTR region. The frequency of carriers of the rare rs62637702 G allele (*94A/G) was significantly lower among the patients compared to healthy controls (n = 418) (0.03 vs. 0.004; p < 0.001), suggesting a protective role for this allele. In order to investigate the basal effect of this variant, we performed luciferase assays. No different basal activity was observed between the two alleles. In conclusion, the rs62637702 polymorphism was associated with PD. This could be a surrogate marker for disease risk, in linkage disequilibrium with other non-identified functional variant.
- 11 November 2011
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 47 (3) , 425-430
A Search for SNCA 3′ UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinson’s Disease
Alpha-synuclein gene (SNCA) polymorphisms have been associated with the common sporadic form of Parkinson’s disease (PD). We searched for DNA variants at the SNCA 3′ UTR through single strand conformation analysis and direct sequencing in a cohort of Spanish PD patients and controls. We have genotyped the rs356165 SNCA 3′ UTR polymorphism in a total of 1,135 PD patients and 772 healthy controls from two Spanish cohorts (Asturias and Navarre). We identified six SNCA 3′ UTR variants. Single nucleotide polymorphism (SNP) rs356165 was significantly associated with PD risk in the Spanish cohort (p = 0.0001; odd ratio = 1.37, 95%CI = 1.19–1.58). This SNP was also significantly associated with early age at onset of PD. Our work highlights rs356165 as an important determinant of the risk of developing PD and early age at onset and encourages future research to identify a functional effect on SNCA expression.
- 11 November 2011
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 47 (3) , 425-430
A Search for SNCA 3′ UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinson’s Disease
Alpha-synuclein gene (SNCA) polymorphisms have been associated with the common sporadic form of Parkinson’s disease (PD). We searched for DNA variants at the SNCA 3′ UTR through single strand conformation analysis and direct sequencing in a cohort of Spanish PD patients and controls. We have genotyped the rs356165 SNCA 3′ UTR polymorphism in a total of 1,135 PD patients and 772 healthy controls from two Spanish cohorts (Asturias and Navarre). We identified six SNCA 3′ UTR variants. Single nucleotide polymorphism (SNP) rs356165 was significantly associated with PD risk in the Spanish cohort (p = 0.0001; odd ratio = 1.37, 95%CI = 1.19–1.58). This SNP was also significantly associated with early age at onset of PD. Our work highlights rs356165 as an important determinant of the risk of developing PD and early age at onset and encourages future research to identify a functional effect on SNCA expression.
- 2 July 2011
- Published by Springer Nature in Journal of Neurology
- Vol. 259 (2) , 246-250
Mitochondrial DNA polymorphisms/haplogroups in hereditary spastic paraplegia
- 2 July 2011
- Published by Springer Nature in Journal of Neurology
- Vol. 259 (2) , 246-250
Mitochondrial DNA polymorphisms/haplogroups in hereditary spastic paraplegia